作者: Robert J Hancox , James Fingleton , Lutz Beckert , Matire Harwood , Richard Beasley
DOI:
关键词: Asthma 、 Budesonide 、 Medicine 、 Mepolizumab 、 Intensive care medicine 、 Guideline 、 Inhaler 、 Formoterol 、 Omalizumab 、 Allergy
摘要: The purpose of the 2020 Asthma and Respiratory Foundation NZ Adolescent Adult Guidelines is to provide simple, practical evidence-based recommendations for diagnosis, assessment management asthma in adolescents adults (aged 12 over) a quick reference format. intended users are health professionals responsible delivering care community hospital settings, those training such professionals. main changes update are: 1) combining both single document, 2) recommendation avoid SABA-only treatment long-term asthma, 3) use budesonide/formoterol reliever, with or without maintenance budesonide/formoterol, preferred SABA ICS ICS/LABA, across spectrum severity, 4) introduction terminology 'anti-inflammatory reliever (AIR)' therapy describe as medication, budesonide/ formoterol therapy. This approach encompasses extends 'Single combination ICS/LABA inhaler Maintenance And Reliever Therapy' (SMART) recommended previous guideline, 5) inclusion two stepwise algorithms, 6) clinical allergy section, 7) role LAMA severe 8) omalizumab allergic mepolizumab eosinophilic 9) an appendix detailing educational materials.